Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Saudi Food And Drug Authority Approves Agios' PYRUKYND For Adults With Thalassemia

Author: Benzinga Newsdesk | August 04, 2025 03:22pm

First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines Program
- Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to manage PYRUKYND commercialization in the Gulf Region

Posted In: AGIO